Kevin Haas Named Chief Development and Technology Officer at Veracyte

Veracyte Inc. has hired Kevin Haas, Ph.D., as chief development and technology officer, a newly created role designed to advance and scale the company’s global product development strategy.

Dr. Haas will oversee Veracyte’s end‑to‑end product development, spanning diagnostic assay development, software and bioinformatics, as well as the product development program office.

As Veracyte’s pipeline expands into whole‑genome minimal residual disease (MRD) and other multi‑omics applications, product development requires integrated capabilities across assays, software, artificial intelligence (AI), and next‑generation informatics to support solutions from diagnosis to disease management. Dr. Haas will lead these efforts to deliver high‑quality laboratory‑developed tests (LDTs) and global in-vitro diagnostic (IVD) products. He will bring these capabilities together to accelerate innovation and support the company’s global portfolio.

“Kevin is an accomplished product development and software leader with a track record of advancing diagnostic innovations and platform technologies,” Veracyte CEO Marc Stapley stated. “His experience across software engineering, data science, and assay development will be critical as we execute on a growing pipeline of tests in development and expand our portfolio to benefit clinicians and patients worldwide.”

Dr. Haas has more than 15 years of life sciences industry experience, leading teams across technology, research, and development. Most recently, he was chief technology officer at Myriad Genetics, where he led development of the company’s precision medicine platform and digital health strategy. Before that, Dr. Haas was senior vice president of engineering at Myriad and vice president of bioinformatics at Myriad Women’s Health. Prior to Myriad, he worked in leadership roles in lab engineering and bioinformatics at Counsyl.

Dr. Haas is adept at creating automated lab technology and AI systems to derive insights from genomics data and at launching scalable molecular assays. He earned a bachelor of science degree from the University of Wisconsin-Madison and a Ph.D. in chemical engineering from the University of California-Berkeley, where he worked on molecular simulation and machine learning to study protein dynamics.

“I am excited to join Veracyte at a time when the company is launching several exciting new tests, which is just the start of an incredibly strong development pipeline,” Dr. Haas said. “The opportunity to help advance this breadth of innovation and development capabilities by bringing new diagnostic solutions for patients facing cancer is incredibly meaningful.”

Veracyte is a global diagnostics company attempting to transform cancer care. The firm strives to empower clinicians with the necessary insights to guide and assure patients when diagnosing and treating cancer. The Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, bioinformatic and AI capabilities, and an evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for the tests, along with new insights to support continued innovation and pipeline development.